Biologicals | Biosimilars in India – Things you need to know · CliniexpertsBiosimilars in India – Things you need to know Biological agents show significant clinical benefits, but their high cost limits their accessibility. The demand for cost-effective options and the patent expiry of biologics have propelled the development of biosimilars or similar biologics. This article covers the key takeaways from the Indian regulatory guidelines for the BiologicalsBlood productsrDNA ProductsRegulatory CDSCOStem cells and cell-based products
Biologicals | Key Insights from the Genome Analysis of the Novel Coronavirus · Cliniexperts Key Insights from the Genome Analysis of the Novel Coronavirus Ever since the first reports of COVID-19 in Wuhan, China, there has been considerable discussion and “debates” on the origin of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19. In January this year, China shared the full RNA sequence rDNA Products
Biologicals | Human Vaccines – Vaccines Developmental Paradigm India · CliniexpertsVaccines are one of the most beneficial and valuable disease prevention measures contributing to long-term health gains. Advancements in research have led to the development of novel vaccines and delivery technologies and this is has caused a paradigm shift in the way diseases are prevented and treated. Even though the field of vaccines have evolved Blood productsCTRIEthics CommitteePhase 1 TrialPhase 2 Trial
